Taikang Asset Management Hong Kong Co Ltd Reduces Stock Position in Thermo Fisher Scientific Inc. $TMO

Taikang Asset Management Hong Kong Co Ltd reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 53.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,975 shares of the medical research company’s stock after selling 5,769 shares during the period. Taikang Asset Management Hong Kong Co Ltd’s holdings in Thermo Fisher Scientific were worth $2,883,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Berkshire Asset Management LLC PA lifted its holdings in Thermo Fisher Scientific by 54.1% in the fourth quarter. Berkshire Asset Management LLC PA now owns 664 shares of the medical research company’s stock worth $385,000 after buying an additional 233 shares during the period. Polar Capital Holdings Plc lifted its holdings in Thermo Fisher Scientific by 7.6% in the fourth quarter. Polar Capital Holdings Plc now owns 61,164 shares of the medical research company’s stock worth $35,441,000 after buying an additional 4,340 shares during the period. Rothschild Wealth LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $250,000. Rakuten Investment Management Inc. lifted its holdings in Thermo Fisher Scientific by 201.9% in the fourth quarter. Rakuten Investment Management Inc. now owns 49,562 shares of the medical research company’s stock worth $28,997,000 after buying an additional 33,146 shares during the period. Finally, Codex Capital Asset Management L.L.C. lifted its holdings in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. Codex Capital Asset Management L.L.C. now owns 13,350 shares of the medical research company’s stock valued at $7,736,000 after purchasing an additional 475 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $472.73 on Wednesday. The company has a market capitalization of $175.68 billion, a P/E ratio of 25.99, a price-to-earnings-growth ratio of 2.10 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm has a 50 day moving average of $478.34 and a 200 day moving average of $525.54. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMO shares. Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Morgan Stanley reiterated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.